Man har tidligere observeret øget risiko for ICH hos patienter med fremskreden HIV/ AIDS svarende til dem i behandling i de kliniske afprøvninger af APTIVUS.
An increased risk of ICH has previously been observed in patients with advanced HIV disease/ AIDS such as those treated in the APTIVUS clinical trials.